Moderna is trading 4.6% higher at $146.80, with no clear company-specific catalyst identified for the September 1, 2026 move.

  • The company announced upcoming investor-conference appearances, but the disclosure does not explain the intraday gain.
  • Attention remains on the $2.6 billion convertible-note offering, scheduled to close September 1.
  • Potential dilution makes the offering an unlikely direct bullish catalyst.